How tafamidis affects lifespan in people with transthyretin amyloid heart disease: plain language summary
This Plain Language Summary of Publication article (PLSP) from Future Cardiology examined patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Researchers compared survival rates between patients who received tafamidis treatment and those who didn’t, specifically looking at survival outcomes at 2.5 and 3.5 years. The study also documented side effects experienced by patients taking tafamidis as part of their treatment regimen.
Visit the site using this link to read the article.
This PLSP is based on an article called ‘Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)’ and was published in the Journal of Cardiac Failure.
Visit JCF using the link to read the original article.